Inventiva announced that AbbVie communicated during their third-quarter financial results on October 28, 2022, that they decided to stop the development of cedirogant (ABBV-157), an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases, following the analysis of a recently concluded nonclinical toxicology study. The Company's cash runway, including the expected $12 million upfront payment from Sino Biopharm and the EUR 25 million from the EIB credit facility, is not impacted by the discontinuation of the cedirogant clinical program and should allow to fund as previously announced operations through fourth quarter of 2023. In 2012, Inventiva and AbbVie signed a multi-year drug discovery collaboration agreement to identify potent RORg inverse agonists for the treatment of several autoimmune diseases.

Inventiva's and AbbVie's joint efforts led to the discovery of cedirogant, which was being evaluated in a Phase II clinical trial at the time of AbbVie's decision to discontinue further clinical development.